Stocks to Buy Today - Stock Message Board, Discussion Forum, Blog
Find the next Dendreon..10 Bagger Potential !!!!!!!!
Urocidin (Bladder Cancer) Phase III Results within 4 Weeks .Lots will want this goldmine in the future. Please do your own Homework .
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!!
Market Cap: 75 Mio $
Cash: 22 Mio $
Price: 1,03 $
Buy rating by Dundee Sec (May 2010)....
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals (ENDP 22.13 ?1.10%) (NASDAQ:ENDP). Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!!
Market Cap: 75 Mio $
Cash: 22 Mio $
Price: 1,03 $
Buy rating by Dundee Sec (May 2010)....
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals (ENDP 22.13 ?1.10%) (NASDAQ:ENDP). Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says
Views: 34
Replies to This Discussion
-
Permalink Reply by Carl Pechstein on -
GOOD PHASE III RESULTS IS COMING VERY SOON !! DONT MISS THE BIG OPPORTUNITY !! GLTA
BNC IS READY TO TAKEOFF
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&perio...
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
-
Permalink Reply by Carl Pechstein on
-
Must be out soon either Phase3 news or Econiche approval news are about to hit the wire.I'm feeling very optimistic . Let's get rolling.
Buy signal is created
http://www.barchart.com/quotes/stocks/BNC.TO
http://www.barchart.com/cheatsheet.php?sym=BNC.TO
http://www.nasd100.com/2010/07/bestrated-canadian-stocks-updated-ju...
Best-Rated Canadian Stocks Updated Jul 11, 2010
TOP 10 Lists; Up on Unusual Volume;Down on Unusual Volume;52-Week Highs; 52-Week Lows
Below are the best-rated Canadian stocksbased on average Wall Street analyst ratings.Each analyst rating is assigned a number ranging from 1 to5, with 1 being the highest rating (STRONG BUY) and 5 being thelowest rating (STRONG SELL). Then the average is calculated torepresent the overall rating of a stock.
Ranking | Company (Ticker) | Average Rating Value |Average Rating
1 Alarm Force Industries (TSE:AF) 1.00 StrongBuy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 AmorfixLife Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 StrongBuy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy STRONG BUY /body>
-
Permalink Reply by Carl Pechstein on
-
Bioniche is moving higher .. I smell good news !
-
Permalink Reply by Carl Pechstein on
-
Another good day ..somthing is cooking
-
Permalink Reply by Carl Pechstein on
-
Some Positive Signs ..
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/bnhlf_endp_bioniche-...
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--
All DMC (Data Monitoring Committee) are Positive !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
-
Permalink Reply by Carl Pechstein on
-
BNC is moving .Should be a huge blastoff coming soon.
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&perio...
http://www.barchart.com/cheatsheet.php?sym=BNC.TO
-
Permalink Reply by Carl Pechstein on
-
UP 15% TODAY ..THE RUNUP HAS JUST BEGUN !!
MARKET CAP OF 80 MIL$ IS A BIG JOKE ..
UROCIDIN FOR BLADDER CANCER IS A REAL BLOCKBUSTER
GET IN NOW BEFORE ITS TOO LATE .THIS STOCK IS A LIFETIME OPPORTUNITY .
PLEASE DO YOUR OWN DD!!!!!!!
-
Permalink Reply by Matt Lauchaire on -
Is this a joke? You can't trade a penny stock that averages 5000 shares traded a day. Well you could but you probably will lose money.
-
Permalink Reply by Carl Pechstein on
-
Ticker is BNC.TO .There´s no volume on BNHLF.PK
-
Permalink Reply by Carl Pechstein on
-
Permalink Reply by Carl Pechstein on
-
RALLLYYYYYYYYYYYYYYYYYYYYYYYYY.GET IN NOW BEFORE ITS TOO LATE
SEE YOU AT 6$+ BY END OF SEPTEMBER !!! GL
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&perio...
-
Permalink Reply by Carl Pechstein on
-
Good News ...
http://finance.yahoo.com/news/Bioniche-University-of-Ottawa-cnw-371...
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology
Press Release Source: Bioniche Life Sciences Inc. On Wednesday August 25, 2010, 7:00 am
- potential animal health and human health applications for reduction of anxiety -
© 2012 Created by Stocks To Buy.
